Stock CUE CUE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
2.08 USD -2.35% Intraday chart for Cue Biopharma, Inc. +46.48% -21.21%
Apr. 08 Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
Apr. 08 North American Morning Briefing : Inflation Data, -2- DJ

Evolution of the average Target Price on Cue Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6.gPzKTDcKq3WBCApNx3pqvLvpJu58J1-KATj1HxgWbqw.58-9NVhE5B7UX1UasUIB-MqOXKYkFQDQeFCsV1B-H8DLzpIhb1DsWPlXSw~f161cb9c503f47a438da6d59a7e4bd8a

Analyst Recommendations on Cue Biopharma, Inc.

Jefferies Starts Cue Biopharma With Buy Rating MT
Piper Sandler Adjusts Price Target on Cue Biopharma to $8 From $7, Maintains Overweight Rating MT
Cue Biopharma Says Phase 1b Trial of CUE-101 With Pembrolizumab Shows 40% Overall Response Rate MT
Stifel Adjusts Cue Biopharma's Price Target to $8 From $9, Keeps Buy Rating MT
Piper Sandler Starts Cue Biopharma at Overweight With $7 Price Target MT
Oppenheimer Adjusts Cue Biopharma's Price Target to $10 From $26, Maintains Outperform Rating MT
JMP Securities Adjusts Cue Biopharma's Price Target to $15 From $30, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Cue Biopharma's Price Target to $26 From $32, Maintains Outperform Rating MT
Craig-Hallum Adjusts Cue Biopharma's Price Target to $26 From $28, Keeps Buy Rating MT
HC Wainwright Starts Cue Biopharma at Buy with $20 Price Target MT
Craig-Hallum Starts Cue Biopharma at Buy with $28 Price Target MT
CUE BIOPHARMA : Berenberg Starts Cue Biopharma at Buy With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.13 USD
Average target price
9.4 USD
Spread / Average Target
+341.31%
High Price Target
15 USD
Spread / Highest target
+604.23%
Low Price Target
6 USD
Spread / Lowest Target
+181.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cue Biopharma, Inc.

Jefferies & Co.
Piper Sandler
Stifel Nicolaus
Oppenheimer
JMP Securities
Craig-Hallum
HC Wainwright

Ratings for Cue Biopharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CUE Stock
  4. Consensus Cue Biopharma, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW